480 related articles for article (PubMed ID: 9861322)
1. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
3. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
4. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia.
Zou M; Shi Y; Farid NR
Cancer; 1994 Jan; 73(1):176-80. PubMed ID: 8275421
[TBL] [Abstract][Full Text] [Related]
5. RET/PTC activation in hyalinizing trabecular tumors of the thyroid.
Papotti M; Volante M; Giuliano A; Fassina A; Fusco A; Bussolati G; Santoro M; Chiappetta G
Am J Surg Pathol; 2000 Dec; 24(12):1615-21. PubMed ID: 11117781
[TBL] [Abstract][Full Text] [Related]
6. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
[TBL] [Abstract][Full Text] [Related]
7. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
9. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
10. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
11. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.
Chua EL; Wu WM; Tran KT; McCarthy SW; Lauer CS; Dubourdieu D; Packham N; O'Brien CJ; Turtle JR; Dong Q
J Clin Endocrinol Metab; 2000 Aug; 85(8):2733-9. PubMed ID: 10946873
[TBL] [Abstract][Full Text] [Related]
13. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
[TBL] [Abstract][Full Text] [Related]
14. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors.
Namba H; Yamashita S; Pei HC; Ishikawa N; Villadolid MC; Tominaga T; Kimura H; Tsuruta M; Yokoyama N; Izumi M
Endocrinol Jpn; 1991 Dec; 38(6):627-32. PubMed ID: 1823030
[TBL] [Abstract][Full Text] [Related]
15. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
16. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
17. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation.
Bounacer A; Wicker R; Caillou B; Cailleux AF; Sarasin A; Schlumberger M; Suárez HG
Oncogene; 1997 Sep; 15(11):1263-73. PubMed ID: 9315093
[TBL] [Abstract][Full Text] [Related]
20. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]